Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shom Goel

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2023
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer PatientsSara M Tolaney, Shom Goel, Jorge Nadal, et al.
The Journal of Experimental Medicine|August 24, 2023
Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancerLestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
The Journal of Experimental Medicine|January 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancerLestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2025
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast CancerShom Goel, Bojana Jovanović, Xiangying Chu, et al.
NPJ Breast Cancer|August 5, 2021
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancerLaura M Spring, Shealagh L Clark, Tianyu Li, et al.
Clinical Breast Cancer|June 26, 2019
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 TrialShom Goel, Sonia Pernas, Zhenying Tan-Wasielewski, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancerSonia Pernas, Jennifer L Guerriero, Sergey Naumenko, et al.
JACC. Heart Failure|August 12, 2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jia Liu, Hao Guo, et al.
Cancer Discovery|October 6, 2025
Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid TumorsCatherine Dietrich, Alec Trub, Antonio Ahn, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2023
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer PatientsSara M Tolaney, Shom Goel, Jorge Nadal, et al.
The Journal of Experimental Medicine|August 24, 2023
Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancerLestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
The Journal of Experimental Medicine|January 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancerLestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2025
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast CancerShom Goel, Bojana Jovanović, Xiangying Chu, et al.
NPJ Breast Cancer|August 5, 2021
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancerLaura M Spring, Shealagh L Clark, Tianyu Li, et al.
Clinical Breast Cancer|June 26, 2019
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 TrialShom Goel, Sonia Pernas, Zhenying Tan-Wasielewski, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancerSonia Pernas, Jennifer L Guerriero, Sergey Naumenko, et al.
JACC. Heart Failure|August 12, 2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jia Liu, Hao Guo, et al.
Cancer Discovery|October 6, 2025
Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid TumorsCatherine Dietrich, Alec Trub, Antonio Ahn, et al.
Pageof 7